Last reviewed · How we verify
NWRD08
At a glance
| Generic name | NWRD08 |
|---|---|
| Sponsor | Newish Technology (Beijing) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL (PHASE2)
- NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL (PHASE1)
- Clinical Study of HPV Therapeutic DNA Vaccine (NWRD08) in Patients With Cervical HPV16 and/or HPV18 Positive (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NWRD08 CI brief — competitive landscape report
- NWRD08 updates RSS · CI watch RSS
- Newish Technology (Beijing) Co., Ltd. portfolio CI